Sandra K. Althouse - Concepedia

Author

Sandra K. Althouse

Indiana University – Purdue University Indianapolis ORCID

Also Known As

Althouse, Sandra, Althouse, Sandra K., M. C. O’Neill, Patrick Ma, S. Althouse, S.K. Althouse, Sandra K. Althouse, Sandra Althouse, Sandra K Althouse, Sandra K. Althouse

259

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

Indiana University – Purdue University Indianapolis Indiana University School of Medicine Indiana University Health Richard L. Roudebush VA Medical Center Indiana University Melvin and Bren Simon Comprehensive Cancer Center

About

Sandra K. Althouse is an author at Indiana University – Purdue University Indianapolis specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	17	873
2	Health Sciences	9	9	494
3	Biostatistics	2	2	35
4	Cell Biology	2	2	58
5	Public Health	1	1	18

Sandra K. Althouse

Publications

Citations

H-Index

Page 1

	Year	Citations
Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy Foster D. Lasley, Edward M. Mannina, Cynthia S. Johnson, Practical Radiation Oncology Treatment VariablesRadiation MedicineHepatologyRadiation TherapyMedicine	2015	188
Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206 Nabil Adra, Lawrence H. Einhorn, Sandra K. Althouse, Annals of Oncology UrologyPhase Ii TrialMedicinePathologyImmune Checkpoint Inhibitor	2017	185
High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience Nabil Adra, Rafat Abonour, Sandra K. Althouse, Journal of Clinical Oncology	2017	167
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179 Greg Andrew Durm, Salma K. Jabbour, Sandra K. Althouse, Cancer	2020	158
A single-cell atlas of the healthy breast tissues reveals clinically relevant clusters of breast epithelial cells Poornima Bhat‐Nakshatri, Hongyu Gao, Sheng Liu, Cell Reports Medicine	2021	115
Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy Chunkit Fung, Howard D. Sesso, AnnaLynn M. Williams, Journal of Clinical Oncology	2017	108
Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer Diane M. Demas, Susan D. Demo, Yassi Fallah, Frontiers in Oncology	2019	73
Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases Benjamin D. Goodman, Edward M. Mannina, Sandra K. Althouse, Practical Radiation Oncology Radiation MedicineHepatic OligometastasesHepatologyRadiation TherapyLiver Physiology	2015	70
Role of Stereotactic Body Radiation Therapy Before Orthotopic Liver Transplantation: Retrospective Evaluation of Pathologic Response and Outcomes Edward M. Mannina, Higinia R. Cárdenes, Foster D. Lasley, International Journal of Radiation OncologyBiologyPhysics Transplantation SurgeryTransplantationHepatologyRadiation TherapyRetrospective Evaluation	2017	57
Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. Greg Andrew Durm, Sandra K. Althouse, Ahad A. Sadiq, Journal of Clinical Oncology Phase Ii TrialMedicineMetronomic TherapyPharmacologyClinical Trials	2018	52

Page 1